Tags : metformin hydrochloride

Glenmark’s Combination Therapy of Remogliflozin Etabonate + Metformin Hydrochloride Receive

Shots: Glenmark has received the regulatory approval to commercialize the combination therapy of remogliflozin etabonate (100mg) + metformin hydrochloride (500/1000mg) as an adjunct to diet and exercise to improve glycemic control in T2D Mellitus patients in India under the brand names ‘Remo-M’ and Remozen-M’ In Apr’2019, Glenmark has received approval of remogliflozin (100mg, bid) based […]Read More

AstraZeneca’s Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA’s Approval

Shots: The approval is based on two P-III studies assessing the combination of dapagliflozin (5mg, 10mg) ,saxagliptin (5mg) and metformin in patients with inadequately controlled Type-2 diabetes for 24wks. The collective studies result demonstrated a reduction in HbA1c (average blood glucose levels) & increment in no. pf patients achieving HbA1c <7% Qternmet XR (qd, PO) […]Read More